Li Lei, Jin Yanling, Li Tiangang, Lv Bijun, Yuan Difen, Li Xiaoya, Yuan Jiali
School of Basic Medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Kunming, Yunnan, China.
Mol Nutr Food Res. 2025 Sep;69(18):e70144. doi: 10.1002/mnfr.70144. Epub 2025 Jun 16.
Fatty liver disease (FLD), encompassing non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD), has become a major global health concern, primarily driven by unhealthy diets and lifestyle changes. Recently, flavonoids, which account for approximately 60% of polyphenolic compounds, have garnered attention for their antioxidant, anti-inflammatory, and immunomodulatory properties in combating metabolic diseases. This review summarizes recent advancements in the therapeutic potential of flavonoid polyphenols for treating FLD, with a focus on their bioactivity and mechanisms of action, interactions with the gut microbiome, and metabolic effects. The review discusses the bioactivity and biomarkers of flavonoids in treating FLD, their similar and differing roles in NAFLD and AFLD, regulation of gut microbiota, and synergistic mechanisms with other polyphenolic compounds. This review provides insights into the potential applications of flavonoids in treating fatty liver disease and suggests future research directions.
脂肪性肝病(FLD),包括非酒精性脂肪性肝病(NAFLD)和酒精性脂肪性肝病(AFLD),已成为全球主要的健康问题,主要由不健康饮食和生活方式改变所致。最近,约占多酚类化合物60%的黄酮类化合物,因其在对抗代谢性疾病中的抗氧化、抗炎和免疫调节特性而受到关注。本综述总结了黄酮类多酚治疗FLD的治疗潜力的最新进展,重点关注其生物活性和作用机制、与肠道微生物群的相互作用以及代谢效应。该综述讨论了黄酮类化合物在治疗FLD中的生物活性和生物标志物、它们在NAFLD和AFLD中的相似和不同作用、肠道微生物群的调节以及与其他多酚类化合物的协同机制。本综述为黄酮类化合物在治疗脂肪性肝病中的潜在应用提供了见解,并提出了未来的研究方向。